Table 2.
Univariate analysis of survival less than or equal to 24 months vs. greater than 24 months
| Characteristics | N | ≤24 months | > 24 months | OR (95% CI) | p-value | |
|---|---|---|---|---|---|---|
| Age (years) | Mean (standard deviation) | 505 | 64.5 (12.7) | 64.19 (11.9) | 0.99 (0.98–1.01) | 0.782 |
| Sex | Male | 198 | 101 (46.3%) | 97 (33.8%) | 1.69 (1.17–2.42) | 0.004 |
| Female | 307 | 117 (56.7%) | 190 (66.2%) | |||
| ECOG * | 0–1 | 432 | 163 (75.1%) | 269 (93.7%) | 0.2 (0.11–0.35) | < 0.001 |
| 2–4 | 72 | 54 (24.9%) | 18 (6.3%) | |||
| Weight loss * | Yes | 102 | 53 (33.3%) | 51 (22.9%) | 0.59 (0.37–0.93) | 0.024 |
| Smoking history * | Never smoker | 273 | 106 (49.3%) | 163 (57.6%) | 0.80 (0.54–1.19) 0.51 (1.20–1.96) | 0.060 |
| Ex-smoker | 168 | 75 (34.9%) | 93 (32.9%) | |||
| Current smoker | 61 | 34 (15.8%) | 27 (9.5%) | |||
| Lives with a smoker * | Yes | 43 | 18 (28.1%) | 25 (22.9%) | 0.76 (0.37–1.53) | 0.446 |
| Distribution of stages | Stage IIIB | 30 | 9 (4.1%) | 21 (7.3%) | 0.54 (0.24–1.21) | 0.133 |
| Stage IV | 475 | 209 (95.9%) | 266 (92.7%) | |||
| Type of mutations** | Exon 19 deletion | 279 | 109 (50.0%) | 170 (59.2%) | 1.45 (1.01–2.07) | 0.039 |
| L858R | 143 | 59 (27.1%) | 84 (29.3%) | 1.11 (0.75–1.65) | 0.586 | |
| Exon 20 insertion | 24 | 16 (7.3%) | 8 (2.8%) | 0.36 (0.15–0.86) | 0.020 | |
| G719X | 17 | 10 (4.6%) | 7 (2.4%) | 0.52 (0.19–1.39) | 0.141 | |
| S768I | 10 | 5 (2.3%) | 5 (1.7%) | 0.75 (0.21–2.64) | 0.660 | |
| L861Q | 2 | 1 (0.5%) | 1 (0.4%) | 0.75 (0.05–12.19) | 1.000 | |
| Unknown | 20 | 12 (5.5%) | 8 (2.8%) | 0.49 (0.19–1.22) | 0.121 | |
| T790M | 146 | 30 (13.8%) | 116 (40.4%) | 4.25 (2.70–6.67) | < 0.001 | |
| T790M + Del19 | 83 | 12 (5.5%) | 71 (24.7%) | 5.64 (2.97–10.71) | < 0.001 | |
| T790M + L858R | 38 | 6 (2.7%) | 32 (11.1%) | 4.43 (1.81–10.80) | < 0.001 | |
| N° de metastatic sites | Average (P25; P75) | 505 | 2 (1; 3) | 1 (1; 3) | 0.75 (0.66–0.86) | < 0.001 |
| N° of patients with metastatic site at diagnosis ** | Bone | 208 | 100 (45.9%) | 108 (37.6%) | 0.71 (0.50–1.01) | 0.062 |
| Lung | 190 | 84 (38.5%) | 106 (36.9%) | 0.93 (0.65–1.34) | 0.713 | |
| Pleural effusion | 136 | 64 (29.4%) | 72 (25.1%) | 0.80 (0.54–1.19) | 0.284 | |
| CNS | 85 | 51 (23.4%) | 34 (11.9%) | 0.44 (0.27–0.71) | 0.001 | |
| Liver | 73 | 44 (20.2%) | 29 (10.1%) | 0.44 (0.27–0.74) | 0.001 | |
| Adrenal glands | 45 | 31 (14.2%) | 14 (4.9%) | 0.31 (0.16–0.60) | < 0.001 | |
| Pericardial effusion | 11 | 4 (1.8%) | 7 (2.4%) | 1.33 (0.38–4.62) | 0.445 |
* Patients do not add up to the exact total (n 505) for some variables due to lack of data
** Patients may add up to more than the total (n 505) since a patient may have one or more mutations or metastatic sites